MDM2 | Jotup

Possible New Hope for Metastatic Cancer Patients: Food and Drug Administration Grants Approval for Clinical Trials For Lamassu's Groundbreaking Cancer Treatment Protocol

Retrieved on:

星期四, 四月 11, 2024

FDA, Cancer, Bangladesh Technical Education Board, Hope, Food, Cleveland Clinic, MD, Peter Anderson, IND, MDM2, Patient, Toxicity, Drug development, SBIR, Growth, Pharmaceutical industry

Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials.

Key Points:

Lamassu Biotech is proud to announce its pioneering effort to combat locally advanced metastatic p53 wild-type tumors has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) to proceed in initiate Phase 1/2a clinical trials.
The trial will investigate novel therapy SA53-OS, a genetically targeted therapy that targets the MDM2 protein, a key regulator of the tumor suppressor p53 gene.
By selectively activating p53, Lamassu aims to induce tumor cell death and inhibit growth, potentially providing a much-needed breakthrough in targeted cancer therapy.
With SA53-OS patented in 69 countries, successful trials could make a significant impact on the global fight against cancer."

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on:

星期一, 四月 8, 2024

MDM2, Apoptosis, ASH, Drug discovery, PD, Patient, Tumor microenvironment, Cancer, Doctor of Philosophy, TPD, Proteomics, AACR, Society, Therapy, Drug development, Downregulation and upregulation, VHL, STAT3, Pharmaceutical industry

WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader, KT-333, were presented in a late-breaking research poster session at the AACR Annual Meeting taking place April 5-10, 2024, in San Diego, California. Additionally, Nello Mainolfi, PhD, Founder, President and CEO, will present in the Major Symposium at the conference highlighting the Company’s unique target selection strategy and strong preclinical to clinical translation observed across the Company’s first-in-class oncology programs, KT-333 and KT-253, a potent and selective degrader of MDM2.

Key Points:

For these reasons, STAT3 degraders may provide a solution to the development of targeted and selective drugs to address multiple STAT3 dependent pathologies.
Additionally, this unique mechanism of action led to induction of proinflammatory anti-tumorigenic transcriptional signatures in the tumor microenvironment.
This has resulted in robust antitumor activity in patients, as reported in the Company’s latest clinical update at the American Society of Hematology (ASH) Annual Meeting in December 2023.
The Company expects to complete both studies and share additional clinical data to inform the programs’ next development steps in 2024 at upcoming medical meetings.

Astex Pharmaceuticals Announce Key Data Presentations at the American Association For Cancer Research (AACR) 2024 Annual Meeting

Retrieved on:

星期三, 四月 3, 2024

Toxicity, Aplastic anemia, AACR, Astex Pharmaceuticals, MDM2, Half-life

ASTX295 is an oral, potent inhibitor of the p53-MDM2 protein-protein interaction that was discovered by Astex using its proprietary structure-based drug design approach.

Key Points:

ASTX295 is an oral, potent inhibitor of the p53-MDM2 protein-protein interaction that was discovered by Astex using its proprietary structure-based drug design approach.
The compound was specifically designed to overcome the on-target toxicity seen in the first generation MDM2 antagonist compounds which have shown dose-limiting haematological toxicities in the clinic.
In contrast, ASTX295 is a potent MDM2 antagonist with a clean CYP/hERG profile and a shorter human half-life allowing for pulsatile pathway modulation while avoiding myelosuppression.
ASTX295 therefore has bone-marrow sparing characteristics which permit a differentiated safety profile to be presented at AACR.

Edgewood Oncology Announces Positive Efficacy Data From Investigator-Sponsored Study of BTX-A51 in Preclinical Models of Liposarcoma

Retrieved on:

星期日, 四月 7, 2024

The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.

Key Points:

The presentation (Abstract 604), “Targeting casein kinase 1 alpha (CK1alpha) and transcriptional CDKs (CDK7/9) in human liposarcomas,” highlighted findings for BTX-A51 in preclinical human models of LPS.
The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1α and CDK9.
“Dedifferentiated liposarcomas (DDLPS) are rare tumors derived from precursors of fat cells which can occur anywhere in the body.
Importantly, preliminary in vivo data in an LPS patient-derived xenograft model reveal that BTX-A51 is well-tolerated under conditions that inhibit tumor growth.

Lamassu Awarded NIH Grant For Breakthrough Cancer Treatment

Retrieved on:

星期二, 三月 12, 2024

CLEVELAND, March 12, 2024 /PRNewswire/ -- Lamassu Bio Inc., a cutting-edge biotech company dedicated to innovative cancer therapies, has been awarded a grant from the National Institutes of Health (NIH) and National Cancer Institute ( NCI) for the development of their groundbreaking treatment for p53 wild-type sarcomas. The $2.05 million grant will help fund the clinical trial integral to this new cancer treatment. The trial will be conducted in collaboration with Cleveland Clinic Taussig Cancer Center and Cleveland Clinic Children's Pediatric Hematology and Oncology Department.

Key Points:

The $2.05 million grant will help fund the clinical trial integral to this new cancer treatment.
Its role in preventing tumor formation by inducing programmed cell death in response to cellular stress makes it a key target for cancer therapy.
This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care.
"The NIH grant will play a pivotal role in facilitating the transition of our research from the laboratory to the bedside.

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Retrieved on:

星期二, 一月 9, 2024

ET

Key Points:

ET
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs.
Sanofi, which is collaborating with Kymera on the development of KT-474 outside of the oncology and immune-oncology fields, is conducting the Phase 2 studies.
KT-621 has potentially broad utility across a number of allergic diseases, including atopic dermatitis, asthma and chronic obstructive pulmonary disorder, among others.
Kymera is working to develop a biomarker-based patient selection strategy for subsequent development beyond Phase 1a.

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on:

星期四, 十一月 2, 2023

ET

Key Points:

ET
WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

Retrieved on:

星期一, 十月 16, 2023

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253. The data was presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 11-15, 2023, in Boston, Massachusetts and will also be shared at the 10th International MDM2 Workshop taking place October 15-18, 2023, in Tokyo, Japan.

Key Points:

p53 remains intact (wild type) in approximately 50% of cancers, meaning that it retains its ability to modulate cancer cell growth.
In preclinical studies, MDM2 degraders have demonstrated the ability to overcome the MDM2 feedback loop observed with MDM2 SMIs and rapidly induce cell death in sensitive p53 wild-type cancer cell lines, even with brief compound exposure.
This may enable an improved therapeutic index, which could result in a superior efficacy and safety profile over MDM2 SMIs.
These data demonstrate in vitro efficacy of an MDM2 degrader, KTX-049, against p53 wild-type MCC cell lines that was achieved with brief compound exposure.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on:

星期二, 八月 22, 2023

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points:

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on:

星期二, 八月 22, 2023

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points:

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.